Takeda Pharmaceutical Patents – Key Insights and Stats

Takeda Pharmaceutical has a total of 37944 patents globally, out of which 13310 have been granted. Of these 37944 patents, more than 58% patents are active. United States of America is where Takeda Pharmaceutical has filed the maximum number of patents, followed by Japan and Europe and it also seems reasonable as the biggest market for Takeda Pharmaceutical is USA, it has generated an annual revenue of $30.05 billion in the year 2021. USA seems to be the main focused R&D center and Japan is the origin country of Takeda Pharmaceutical.

Takeda Pharmaceutical was founded in the year 1781 by Chobei Takeda. Company is doing business in manufacturing drugs, and is one of the 20 largest pharmaceutical companies in the world. As of December 2021, Takeda Pharmaceutical has a market cap of $43.74 Billion.

Do read about some of the most popular patents of Takeda Pharmaceutical which have been covered by us in this article and also you can find Takeda Pharmaceutical’s patents information, the worldwide patent filing activity and its patent filing trend over the years, and many other stats over Takeda Pharmaceutical’s patent portfolio.

How many patents does Takeda Pharmaceutical have?

Takeda Pharmaceutical has a total of 37944 patents globally. These patents belong to 9174 unique patent families. Out of 37944 patents, 22041 patents are active.

How many Takeda Pharmaceutical patents are Alive/Dead?

Worldwide Patents

Takeda Pharmaceutical Worldwide Legal Trends

Patent Families

Takeda Pharmaceutical Patent Portfolio

How Many Patents did Takeda Pharmaceutical File Every Year?

Takeda Pharmaceutical Patent Filing Trend

Are you wondering why there is a drop in patent filing for the last two years? It is because a patent application can take up to 18 months to get published. Certainly, it doesn’t suggest a decrease in the patent filing.

Year of Patents Filing or GrantTakeda Pharmaceutical Applications FiledTakeda Pharmaceutical Patents Granted
20112134856
20121925971
201316901015
201418821027
20151594906
20161179934
201712181016
20181209995
201910781004
2020643865
2021283701

Which Takeda Pharmaceutical Drug Patents are Expiring in the Next 10 Years?

The patent no. US9974835B2 which is expiring in May, 2026, describes the Study for improvement of intestinal absorption in short bowel syndrome patients with a colon by using a GLP-2 receptor agonist, like teduglutide.

Given below is the list of few drugs patented by Takeda Pharmaceutical accompanied by a patent relevant to the drug which will be available for generic drug manufacturing and usage within the next/upcoming 10 years for treatment of various diseases and disorders.

Drug NamePatent NumberPatent TitlePatent Expiration
Gattex KitUS9974835B2Treatment Of Short Bowel Syndrome…May, 2026
TrintellixUS9278096B2Therapeutic Uses Of Compounds Having…Mar, 2032
ColcrysUS8440721B2Methods For Concomitant Admin…Feb, 2029
DexilantUS8871273B2Method For Producing GranulesJan, 2028
NinlaroUS8871745B2Proteasome InhibitorsAug, 2027

How Many Patents did Takeda Pharmaceutical File in Different Countries?

Takeda Pharmaceutical Patent Portfolio in top 10 countries

Countries in which Takeda Pharmaceutical Filed Patents

CountryPatents
United States Of America5144
Japan3512
Europe2955
Australia2666
Canada1688
China1374
Korea (South)1055
Hong Kong (S.A.R.)922
Mexico863
India793
Brazil770
Israel724
Singapore686
Taiwan681
Spain680
Argentina518
Eurasia464
South Africa436
New Zealand436
Peru420
Denmark412
Poland370
Germany361
Turkey338
Austria332
Portugal327
Thailand307
Vietnam306
Philippines277
Norway274
Malaysia272
Chile264
Colombia247
Slovenia246
Russia232
Morocco225
Croatia219
United Kingdom211
Costa Rica208
Indonesia195
Cyprus184
Hungary179
Dominican Republic177
Ukraine171
Ecuador169
Serbia158
Uruguay156
Tunisia135
Georgia124
Lithuania87
Montenegro64
Africa69
Jordan39
Iceland39
Gulf Cooperation Council37
Czech Republic33
Slovakia27
San Marino21
Kazakhstan17
Nicaragua15
Belarus13
Cuba13
Guatemala12
Estonia12
Netherlands11
Bulgaria10
Luxembourg8
Saudi Arabia8
Honduras6
Finland5
El Salvador3
Panama3
Belgium2
Mongolia2
France1
Algeria1
Sweden1
Republic of Moldova1
Egypt1
Italy1

Where are Research Centers of Takeda Pharmaceutical Patents Located?

Takeda Pharmaceutical R&D Centers

10 Best Takeda Pharmaceutical Patents

US20030092019A1 is the most popular patent in the Takeda Pharmaceutical portfolio. It has received 372 citations so far from companies like Medtronic, Metamorphix and Applera Corporation.

Below is the list of 10 most cited patents of Takeda Pharmaceutical:

Publication NumberCitation Count
US20030092019A1372
US20100324936A1274
US20030186374A1252
US6913768B2206
WO2011022439A1201
WO2005095381A1197
WO2004041201A2190
WO2009143389A1188
WO2003099773A1183
JP2003519698A182

Which Companies are using Takeda Pharmaceutical Patents to Advance their Research?

If patents or patents from a particular technology area of a company receive a lot of citations, it implies that the technology is being followed and incrementally innovated by the citing companies. It also indicates that citing companies are working on similar and closely related technologies.

The top citing companies in the Takeda Pharmaceutical patent portfolio are Baxalta, Shire and National Institutes Of Health.

List of the top forward citing Companies –

CompanyNumber of Patents
Baxalta64
Shire44
National Institutes Of Health43
Weatherford28
Translate Bio25
Novartis20
Halliburton17
Life Technologies16
Kempharm13
Apple12

Count of 102 and 103 Type Rejections based on Takeda Pharmaceutical Patents

Takeda Pharmaceutical Patent Portfolio

Top Takeda Pharmaceutical Patents used in Rejecting Most Patent Applications

Patent NumberCount of Rejected Applications
US20100324936A139
US7836973B235
US7384783B228
US8050461B219
US20110244026A117
US8304524B215
US8603805B214
US8546548B214
US8193182B214
US8390821B213

What Percentage of Takeda Pharmaceutical US Patent Applications were Granted?

Takeda Pharmaceutical (Excluding its subsidiaries) has filed 2142 patent applications at USPTO so far (Excluding Design and PCT applications). Out of these 1473 have been granted leading to a grant rate of 73.58%.

Below are the key stats of Takeda Pharmaceutical patent prosecution at the USPTO.

Which Law Firms Filed Most US Patents for Takeda Pharmaceutical?

Law FirmTotal ApplicationSuccess Rate
Wenderoth Lind & Ponack L L P28071.74%
Foley & Lardner Llp22971.08%
Mintz Levin Special Group18660.89%
Takeda California Inc15868.61%
Morgan Lewis & Bockius Llp Sf Baxter13591.67%
Takeda Pharmaceuticals North America Inc13363.16%
Troutman Pepper Hamilton Sanders Llp10197.80%
Hamre Schumann Mueller & Larson P C9764.95%
Locke Lord Llp8859.09%
Foley & Lardner8298.78%

“Takeda is committed to strive towards better health for patients worldwide through leading innovation in medicine.”

Takeda Pharmaceutical R&D is on a never-ending quest for scientific breakthroughs in order to bring transformative therapies to patients all over the world. This necessitates a large network of experts, unparalleled knowledge in its primary treatment areas, and world-class resources. Takeda is cultivating an ecosystem of innovation to integrate cutting-edge science into significant health solutions through collaborations, collaboration, and research.

Takeda Pharmaceutical is focusing on therapeutic areas where it wants to be at the forefront of innovation: oncology, gastroenterology (GI), and central nervous system (CNS) disease areas where there is a high level of patient need, where it can leverage its deep scientific expertise, where it has a strong track record of recent successes, and where it plans to continue discovering innovative new medicines. Takeda’s global health strategy to vaccines, which was predicated on its dengue and norovirus initiatives, is being expanded.

EXCLUSIVE INSIGHTS COMING SOON!

What are Takeda Pharmaceutical key innovation segments?

What Technologies are Covered by Takeda Pharmaceutical?

The chart below distributes patents filed by Takeda Pharmaceutical in different countries on the basis of the technology protected in patents. It also represents the markets where Takeda Pharmaceutical thinks it’s important to protect particular technology inventions.

R&D FocusHow Takeda Pharmaceutical search focus changed over the years?

EXCLUSIVE INSIGHTS COMING SOON!

Interested in knowing about the areas of innovation that are being protected by Takeda Pharmaceutical?

Related Articles

Computime Patents – Insights & Stats (Updated 2024)

Computime has a total of 224 patents globally, out of which 115 have been granted. Of these 224 patents, more than 63% patents are active. The United States of America is where Computime has filed the maximum number of patents, followed by Europe (EPO) and Germany. Parallelly, United States of

Read More »

Was this article helpful?

Leave a Comment

Fill the form to get the details:

Fill the form to get the details:

Our comprehensive report provides an in-depth look into the patent portfolio. The report includes a breakdown of the patent portfolio across various technologies, listing the patent along with brief summaries of each patent's technology.